镥-177标记PSMA示踪剂用于前列腺癌核素治疗的广泛临床前评估
该临床前研究比较了临床应用的PSMA靶向小分子抑制剂DOTA-PSMA-617、DOTAGA-PSMA-I&T及PSMA纳米抗体DOTA-JVZ-007的PSMA结合亲和力、生物分布和DNA损伤能力。结果显示[177Lu]Lu-PSMA-617在PSMA阳性细胞及人肾和唾液腺组织中的结合特征更有利,小鼠生物分布最优;[177Lu]Lu-PSMA-I&T在注射后4和8小时肾脏摄取约高40倍,肿瘤/肾脏比不利。
要点
- 三种示踪剂IC50均在纳摩尔范围,JVZ-007结合位点不同。
- PSMA-617与PSMA-I&T肿瘤摄取和DNA双链断裂诱导相似。
- PSMA-I&T肾脏摄取高约40倍,肿瘤/肾脏比不利。
核心结论
- 与[177Lu]Lu-PSMA-I&T和[177Lu]Lu-JVZ-007相比,[177Lu]Lu-PSMA-617在小鼠中生物分布最有利,在PSMA阳性细胞及人肾和唾液腺标本中体外结合特征更有利。
研究设计与样本
- 临床前研究,使用PSMA表达细胞系、前列腺癌患者来源异种移植(PDX)及健康人组织,评估DOTA-PSMA-617、DOTAGA-PSMA-I&T和DOTA-JVZ-007三种示踪剂。
主要发现
- 体外置换实验显示三种镥-177标记示踪剂对PSMA阳性细胞和PSMA阳性PDX冷冻切片的IC50均在纳摩尔范围,结合亲和力高且特异。
- [177Lu]Lu-JVZ-007不能被PSMA-617或PSMA-I&T置换,提示其靶向替代结合位点。
- 人唾液腺和肾组织冷冻切片放射自显影显示[177Lu]Lu-PSMA-617对健康器官的结合低于[177Lu]Lu-PSMA-I&T。
- 体内生物分布显示[177Lu]Lu-PSMA-617与[177Lu]Lu-PSMA-I&T在所有时间点肿瘤摄取相当,诱导相似水平的肿瘤DNA双链断裂。
- [177Lu]Lu-PSMA-I&T在注射后4和8小时肾脏摄取约高40倍,导致不利的肿瘤/肾脏比。
临床怎么用
- 基于该临床前评估,[177Lu]Lu-PSMA-617是表现最佳的示踪剂,可进一步进入临床评估用于PSMA靶向放射性治疗开发。
- 需仔细评估示踪剂与PSMA表达器官的结合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Various radiolabeled prostate-specific membrane antigen (PSMA)-targeting tracers are clinically applied for prostate cancer (PCa) imaging and targeted radionuclide therapy. The PSMA binding affinities, biodistribution, and DNA-damaging capacities of these radiotracers have not yet been compared in detail. A major concern of PSMA-targeting radiotracers is the toxicity in other PSMA-expressing organs, such as the salivary glands, thus demanding careful evaluation of the most optimal and safest radiotracer. In this extensive preclinical study, we evaluated the clinically applied PSMA-targeting small molecule inhibitors DOTA-PSMA-617 (PSMA-617) and DOTAGA-PSMA-I&T (PSMA-I&T) and the PSMA nanobody DOTA-JVZ-007 (JVZ-007) using PSMA-expressing cell lines, a unique set of PCa patient-derived xenografts (PDX) and healthy human tissues. METHODS AND RESULTS: In vitro displacement studies on PSMA-expressing cells and cryosections of a PSMA-positive PDX revealed high and specific binding affinity for all three tracers labeled with lutetium-177 with IC50 values in the nanomolar range. Interestingly, [177Lu]Lu-JVZ-007 could not be displaced by PSMA-617 or PSMA-I&T, suggesting that this tracer targets an alternative binding site. Autoradiography assays on cryosections of human salivary and renal tissues revealed [177Lu]Lu-PSMA-617 to have the lowest binding to these healthy organs compared with [177Lu]Lu-PSMA-I&T. In vivo biodistribution assays confirmed the in vitro results with comparable tumor uptake of [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T at all timepoints, resulting in induction of similar levels of DNA double-strand breaks in the tumors. However, [177Lu]Lu-PSMA-I&T demonstrated approximately 40× higher renal uptake at 4 and 8 h post injection resulting in an unfavorable tumor-to-kidney ratio. CONCLUSION: [177Lu]Lu-PSMA-617 has the most favorable biodistribution in mice as well as more favorable binding characteristics in vitro in PSMA-positive cells and human kidney and salivary gland specimens compared with [177Lu]Lu-PSMA-I&T and [177Lu]Lu-JVZ-007. Based on our preclinical evaluation, [177Lu]Lu-PSMA-617 is the best performing tracer to be taken further into clinical evaluation for PSMA-targeted radiotherapeutic development although with careful evaluation of the tracer binding to PSMA-expressing organs.
引用
- Ruigrok EAM, van Vliet N, Dalm SU, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020. PMID: 33094433. doi:10.1007/s00259-020-05057-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。